BioNTech's stock fell to $102.38 after the company announced it had scrapped its Phase 2 BNT122-01 colorectal cancer vaccine trial, developed with Genentech, as an independent Data Safety Monitoring Board concluded that continuing the trial would not change the efficacy outcome. The news also caused Moderna's stock to drop 6% to $134.48, as investors trimmed exposure to mRNA cancer vaccines, while Pfizer's shares remained largely flat despite its partnership with BioNTech on COVID shots.